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Abstract
Background: Respiratory syncytial virus (RSV) is associated with significant mortality rates amongst hematopoietic
stem cell transplant (HSCT) recipients, with less known about other immunocompromised patients.
Methods: Ten-year retrospective cohort study of immunocompromised patients presenting with RSV disease
documented at University Hospitals of Lausanne and Geneva. Severe RSV-related outcomes referred to RSV documented
respiratory conditions requiring hospital admission, presenting as lower respiratory tract infection (LRTI) or pneumonia. We
used multivariable logistic regression to assess clinical and laboratory correlates of severe RSV disease.
Results: From 239 RSV-positive immunocompromised in and out-patients 175 were adults and 64 children of whom 111
(47.8%) presented with LRTI, which resulted in a 38% (89/239) admission rate to hospital. While immunocompromised
children were more likely to be admitted to hospital compared to adults (75% vs 62.9%, p = 0.090), inpatients admitted to
the intensive care unit (17/19) or those who died (11/11) were mainly adults. From multivariable analyses, adults with
solid tumors (OR 5.2; 95% CI: 1.4–20.9 P = 0.015) or those requiring chronic immunosuppressive treatments mainly for
rheumatologic conditions (OR 4.1; 95% CI: 1.1–16.0; P = 0.034) were significantly more likely to be admitted to hospital
compared to hematopoietic stem cell (HSCT) recipients. Bacterial co-infection was significantly and consistently associated
with viral LRTI and pneumonia.
Conclusions: From our findings, RSV-related disease results in a significant burden among adults requiring chronic
immunosuppressive treatments for rheumatological conditions and those with solid tumors. As such, systematic
screening for respiratory viruses, should be extended to other immunocompromised populations than HSCT recipients.
Background
Respiratory syncytial virus (RSV), a single-stranded virus
of the paramyxoviridae family, is the most important
viral etiologic agent of lower respiratory tract infection
(LRTI) in infants and young children worldwide [1, 2].
Although mortality rates in healthy infants with RSV
pneumonia are less than 0.5%, they can reach up to 60%
in untreated immunocompromised children or adults.
The burden of RSV infections is well described in adult
hematopoietic stem cell transplant (HSCT) recipients in
whom progression from upper respiratory tract (URTI)
to LRTI is frequent (40 to 60% of cases) with mortality
rates approaching 80%. Recent evidence also supports
immunomodulatory effects of RSV infections among
lung transplant recipients, in whom a significant associ-
ation between the development of chronic lung allograft
dysfunction (CLAD) and RSV infections has recently
been reported [3–8].
To date, published reports of RSV infections in im-
munocompromised patients have primarily focused on
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adult HSCT recipients with much less known in other
adult and pediatric immunocompromised settings [3–7].
Given the lack of information on the burden of RSV in-
fections in other immunocompromised adult and pediatric
populations than HSCT recipients, it is essential to obtain
further information on the risk factors and outcomes of se-
vere RSV disease among immunocompromised patients.
This is important to optimize the prevention of severe RSV
disease in this patient population.
This primary objective of this study was to describe
the burden and characteristics of RSV infections in a
broad population of immunocompromised adults and
children. Our secondary objective, was to identify the
risk factors for severe RSV infections defined as hospital
admission, LRTI and pneumonia.
Methods
Study population and definitions
From January 1, 2005 to December 31, 2014, we con-
ducted a multi-center observational study of children and
adults presenting with an immunodeficiency state who
presented with an RSV-URTI or LRTI in an ambulatory
setting or upon or during their admission to the Univer-
sity hospitals of Lausanne and Geneva, Switzerland. RSV-
positive patients were identified from Laboratory records.
Clinical and laboratory data on RSV-positive immuno-
compromised adults and children were collected retro-
spectively with the assistance of hospital medical records.
All children less than 18 years of age and adults presenting
with at least one of the following conditions were in-
cluded: allogeneic or autologous HSCT recipients, solid
organ transplant (SOT) recipients, patients on cancer
chemotherapy or long-term immunosuppression for any
chronic disease, which included mostly patients with an
underlying rheumatologic condition and those with Con-
nective Tissue Disease (CTD) (Additional file 1: Table S1);
and primary immunodeficiency disease (PID). Immuno-
compromised children with other comorbidities qualifying
for RSV prophylaxis based on current Swiss guidelines [8]
and patients with human immunodeficiency virus (HIV)
were excluded. We defined URTI as detection of RSV in
upper respiratory secretions together with symptoms only
involving the upper respiratory tract and LRTI as any
RSV-positive patient associated with cough, tachypnea
and any respiratory distress or wheezing Pneumonia
was defined as any of the above LRTI symptoms with
pulmonary infiltrates reported by a radiologist on
chest radiography and the exclusion of other causes as de-
fined elsewhere [9, 10]. Acute-respiratory-tract infection
(ARTI)-attributable hospital admission included patient
admitted for respiratory symptoms with concomitant
documentation of RSV in a respiratory samples. Severe
neutropenia was defined as an absolute neutrophil
count (ANC) < 500 cells/μl and severe lymphopenia as an
absolute lymphocyte count (ALC) < 100 cells/μl [11]. Ap-
proval was obtained from the Research Ethics Boards at
University hospitals of Lausanne and Geneva.
Collection of clinical information
Information on patient demographic variables such as
age, gender, type of immunosuppression, bacterial and
viral co-infection, median ANC or ALC counts, oral ri-
bavirin or palivizumab treatments were all abstracted
from health records. Primary outcome referred to acute
respiratory tract infection (ARTI)-attributable hospital ad-
mission. Secondary outcomes consisted of the documen-
tation of LRTI or pneumonia, intensive care unit (ICU)
admission and RSV-contributed mortality within 30 days
of the diagnosis of RSV infection. RSV-attributable admis-
sion to the intensive care unit (ICU) was defined as a
documented RSV disease requiring admission to the
ICU. Overall mortality referred to death from any cause
whereas RSV-contributed mortality was defined as a per-
sistent or progressive RSV infection with respiratory fail-
ure documented at the time of death [12]. Each case was
adjudicated by 2 members of the study team.
Virology studies
From 2005 to 2013, nasopharyngeal specimens, broncho-
alveolar lavage (BAL) fluids and sputum samples were ex-
amined by a two-step reverse transcriptase polymerase
chain reaction (RT-PCR) assay, targeting RSV A and B.
This assay is extensively validated at the Laboratory of
Virology, University Hospitals Geneva. In addition, speci-
mens collected from children, which required immediate
identification for cohorting purposes, were tested by a
rapid antigen assay for RSV (RSV Respi-Strip, Coris
Bioconcept) [13, 14] A commercial one-step PCR FTD
Respiratory pathogens 21 (ref.FTD.-53–96/12) from Fast-
Track Diagnostics (Luxembourg) (used at University hos-
pitals Geneva since 2013) and the Cepheid Xpert Flu/RSV
(used at University hospital Lausanne since 2015) further
replaced molecular and rapid antigen assays [15, 16]. A
patient was defined as being RSV-positive if any specimen
was positive by any diagnostic method (antigen assay
or any of the above listed molecular assay). Multiple
simultaneous virus infections (herein referred to as viral
co-infection) were those in which two or more virus path-
ogens were detected from the same respiratory sample.
Bacterial co-infection was defined as the presence of any
bacterial pathogen, identified by culture from blood or
respiratory samples upon initial consultation with re-
spiratory symptoms or within 30 days of their initial
consultation in association with a documented viral infec-
tion.We excluded children if blood culture isolates were
considered to be contaminants based on international
guidelines [17].
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Statistical analyses
Standard descriptive and comparative statistics (the Fish-
er’s exact test for categorical variables and the Mann-
Whitney U test for continuous variables) were used on
data categorized by age groups (children under 18 years
of age and adults) and in and outpatients. For all statis-
tical testing, only the first RSV-positive nasopharyngeal
swab was included in cases with multiple RSV-positive
swabs within the same patient because these samples
cannot be considered independent. Univariable and mul-
tivariable logistic regression were used to assess clinical
and laboratory correlates of ARTI-attributable hospital
admission, LRTI and pneumonia with stratified analyses
for children and adults. Predictor variables included
different immunosuppressive categories, age, bacterial
infection, and ALC for all patients and the adult sub-
group whereas only bacterial co-infection and ALC were
included in the children subgroup given the small num-
ber of observations. Statistically significant predictors in
univariable analyses were included in multivariable ana-
lyses [18]. All analyses were conducted by complete case
analyses, excluding all patients with missing values for
any dependent or independent variables. We evaluated
next the robustness of the estimates related to the po-
tential differences in disease severity described for i)
HSCT recipients infected with RSV within 2 years of
transplantation; ii) patients who presented with viral co-
infections and iii) patients detected RSV-positive by mo-
lecular assays solely. Therefore, we performed three post
hoc sensitivity analyses for primary and secondary out-
comes: one in which HSCT recipients infected with RSV
after two years from their transplantation were excluded,
another one excluding all 52 patients with viral co-
infections and one excluding 12 children detected RSV-
positive by rapid antigen assays only. Two sided tests
were performed, and a P value < 0.05 was considered to
be statistically significant. Data were analyzed using SPSS
statistical software (version 20.0, SPSS Inc., Chicago, IL,
USA), SAS and R (version 3.3.3, R Foundation for Statis-
tical Computing, Vienna, Austria).
Results
Descriptive characteristics of study subjects
Three thousand two hundred and twenty-three RSV-
positive patients (4′605 positive RSV samples) of whom
239 (7.4%) were eligible RSV-positive immunocomprom-
ised subjects (64 (26.8%) children and 175 adults (73.2%)
(Additional file 1: Figure S1). From all patients, HSCT
recipients (N = 67; 28.0%) and SOT recipients (N = 63;
26.4%) were the most common immunosuppressive condi-
tions included. Most of the 64 children, 35 (54.7%) males,
with a median age of 4.9 years (interquartile range [IQR]
3.2–7.7) presented with leukaemia or lymphoma (N = 29;
45.3%), whereas HSCT (N = 59, 33.7%) and SOT (N = 58,
33.1%) were the most common immunosuppressive condi-
tions documented among the 175 adults (Table 1).
Proportion of RSV-positive specimens, bacterial and
viral-co-infections
RSV was detected positive from 202 (84.5%) nasopha-
ryngeal (NP) swabs and 35 (15%) BAL, of which 25
(28.6%) were collected from patients with pneumonia.
Two hundred and twenty-seven patients (95%) were de-
tected by molecular assays and 12 (5%) by rapid antigen
assays. From all patients, 36 (15.1%) presented with a
documented bacterial co-infection, of whom 29 (80.6%)
with bacteremia and 7 (19.4%) with bacterial pneumonia
documented from BAL. From the 11 patients who died,
only 3 (27.3%) presented with a bacterial co-infection
(S. aureus, Stenotrophomonas maltophilia and Legion-
ella pneumophila) documented from BAL. 52 (21.8%)
patients presented with a viral co-infection of whom
10 (19.2%) had more than two viruses detected. The
most common viral co- infections were human rhino-
virus/enterovirus-RSV (16/42; 38.1%), parainfluenza
(PIV)-RSV (6/42; 14.3%) and influenza (FLU)-RSV (6/
42; 14.3%) (Table 1).
Clinical outcomes
From all immunocompromised subjects, 89 (37.2%)
(N = 58; 34.1% adults; N = 31; 48.4% children; p = 0.090)
were admitted to hospital for their RSV infection with a
median duration of stay of 5 days (IQR: 0–18 days).
From those 89, 19 (21.3%) patients were admitted to in-
tensive care of whom 6 (31.6%) presented with chronic
disease requiring underlying immunosuppressive ther-
apy, 4 (21.1%) with solid tumors and 4 (21.1%) with
HSCT. Patients admitted to the ICU, requiring mechan-
ical ventilation and those who died were almost all
adults. Likewise immunocompromised adults presented
with significantly higher rates of pneumonia (36.9% vs.
18.8%, p = 0.008) compared to immunocompromised
children. Furthermore, all 11 adults who died within
30 days of their RSV-attributable admission, presented
with pneumonia despite ribavarin (N = 6, 54.5%) or
palivizumab (N = 2,18.2%) administration. Most of those
11 patients, median age of 64.6 years (IQR 34.1–73.9),
were HSCT recipients (N = 4, 36.4%) or presented
with lymphoma/leukemia (N = 3, 27.3%) or solid tumors
(N = 3; 27.3%) (Table 2).
Predictors of hospitalization
From multivariable analyses, we identified that patients
with leukaemia/lymphoma (odds ratio [OR] 3.9; 95%
confidence interval [CI]: 1.7–9.7; P = 0.002), solid tumors
(OR 7.4; 95% CI: 2.7–21.9; P < 0.001) or those requiring
chronic immunosuppression mainly for vasculitis (OR 9.5;
95% CI: 3.3–30.2 P < 0.001) when compared to HSCT,
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Table 1 Baseline characteristics of immunocompromised patients with RSV infection
Variable; number (%) unless indicated otherwise CHILDREN N = 64 ADULTS N = 175 TOTAL N = 239
Variable; number (%) unless indicated otherwise INPATIENTS OUTPATIENTS INPATIENTS OUTPATIENTS INPATIENTS OUTPATIENTS
N = 48 N = 16 N = 107 N = 68 N = 155 N = 84
< 2 years 11 (23) 2 (12.5)
2–5 years 13 (27.1) 7 (43.75)
5–18 years 24 (50) 7 (43.75)
Age (years) median (IQR) 4.9 (2.7–7.4) 47 (.3.7–8.8) 60.5 (48–70.6) 50.8 (37.3–59.4)
Male 26 (54.2) 9 (56.3) 53 (49.5) 34 (20) 79 (51) 43 (51,2)
HSCT 2 (4.2) 6 (37.5) 24 (22.4) 35 (51.5) 26 (16.8) 41 (48.8)
Autologous 0 0 9 (8.4) 1 (1.5) 9 (5.8) 1(1.2)
Allogeneic 0 8(100) 15 (14) 34 (50) 12(7,7) 45(53,6)
Matched 0 3 (18.8) 5 (4.7) 19(28) 5(3,2) 22(26,2)
Mismatched 0 0 1 (1) 0 1(0,6) 0
Unrelated 2 (4.2) 1 (6.3) 9 (8.4) 15(22,1) 11(7,1) 16(19)
SOT 3(6.3) 2 (12.5) 32 (30) 26(38,2) 35(22,6) 28(33,3)
Leukaemia /lymphoma 23 (47.9) 6 (37.5) 18 (16.8) 3(4,4) 41(26,5) 9(10,7)
Solid tumor 9 (18.8) 2 (12.5) 15 (14) 1(1,5) 24(15,5) 3(3,6)
Chronic immuno-suppression 6 (12.5) 0 18 (16.8) 2 (3.0) 24(15,5) 2(2,4)
PID 5 (10.4) 0 0 1(1) 5(3,2) 1(1,2)
GVHD among allogeneic HSCT recipients 1 (2.1) 4 (25) 9 (8.4) 21 (30.9) 10(6,5) 25(29,8)
Bacterial co-infection 8 (16.7) 1(6.3) 25 (23.4) 2 (3) 33(21,3) 3(3,6)
Viral co-infection 12 (25) 6 (37.5) 22 (20.6) 12 (17.7) 34(21,9) 18(21,4)
ANC, median, (IQR) 1.1 (0.5–3.1) 1.7 (1.6–4.2) 4.6 (1.4–8.1) 3.5 (2.6–5.3) 3.4 (0.9–6.7) 3.3 (2.3–5.3)
ALC, median (IQR) 0.8 (0.2–2.1) 1.6 (0.7–1.9) 0.7 (0.1–1.1) 1.1 (0.6–1.9) 0,7(0,2–1,4) 1.1 (0.6–1.9)
Oral ribavirin treatment 1 (2.1) 1 (6.3) 24 (22.4) 12 (17,6) 25 (16.1) 13(15,5)
Palivizumab treatment 2 (4.2) 0 7 (6.5) 1 (1.5) 9 (5,8) 1(1,2)
Absolute neutrophil counts (ANC), Absolute lymphocyte counts (ALC), Graft vs. host disease (GVHD), Hematopoietic stem cell transplant (HSCT), Interquartile range
(IQR), Primary Immunodeficiency Disease (PID), Solid Organ Transplant (SOT)
Number of missing values: Children outpatients: ANC N = 1, ANC =1; adult inpatients ANC N = 5, ALC N = 5; adult outpatients ANC N = 13, ALC N = 13
Table 2 Clinical outcomes of immunocompromised patients with RSV infection
Variable, Number; (%) unless indicated otherwise Children (N = 64) Adult (N = 175) p value Total (N = 239)
All-cause admission to hospital
(adults: 5 missing values)
48 (75.0) 107 (62.9) 0.090 155 (66.2)
ARTI-attributable hospital admissiona
(adults: 5 missing values)
31 (48.4) 58 (34.1) 0.050 89 (38.0)
• Length of hospital stay (d) mean (SD)a • 5 (3.5) • 9 (12.0) • < 0.001 • 7 (9.0)
• Admission to the ICUa • 2 (6.5) • 17 (29.3) • 0.014 • 19 (21.3)
• Use of mechanical ventilationa • 1 (3.2) • 13 (22.4) • 0.029 • 14 (15.7)
• Mortality within 30 days of admissiona • 0 • 11 (19.0) • 0.007 • 11 (12.4)
All-cause mortality within 30 days of admission 1 (1.6) 20 (11.4) 0.018 21 (8.8)
LRTI b(adults: 7 missing values) 26 (40.6) 85 (50.6) 0.188 111 (47.8)
RSV-attributable pneumoniab 12 (18.8) 62 (36.9) 0.008 74 (31.9)
• RSV documented from BALb 2 (16.7) 23 (37.1) 0.024 25 (33.8)
• RSV-bacterial co-infection documented from BAL 0 7 (11.3) 0.020 7 (9.5)
aRefers to patients admitted to hospital for an acute-respiratory-tract infection (ARTI)-attributable hospital admission (i.e excluded patients admitted to hospital for
other reasons). bRefers to all patients seen in an ambulatory setting or admitted to hospital for their RSV infection or for another reason. BAL: Bonchoalveolar lavage,
SD: Standard deviation, LRTI: Lower respiratory tract infection (adults 7 missing values); d: days. RSV-attributable pneumonia (7 missing values)
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were significantly more likely to be admitted to hospital
for RSV. When stratified by age groups (adults vs. chil-
dren), increasing age (OR 1.4; 95% CI: 1.0–1.8 P = 0.027),
patients with solid tumors (OR 5.2; 95% CI: 1.4–20.9;
P = 0.015) and those requiring any chronic immunosup-
pression mainly for vasculitis (OR 4.1; 95% CI: 1.1–16.0;
P = 0.034) when compared to HSCT, remained significant
predictors of ARTI-attributable hospital admission among
adults. Post-hoc sensitivity analyses did not affect our risk
estimates and the above findings (Table 3, Additional file
1: Tables S2, S4 and S6).
Predictors of LRTI and pneumonia
From multivariable analyses, patients presenting with a
bacterial co-infection were significantly more likely to
present with LRTI (OR 3.4; 95% CI: 1.5–8.2; P = 0.005) and
pneumonia (OR 3.6; 95% CI: 1.6–8.4; P = 0.002). When
stratified by age groups (adults vs. children), bacterial
co-infection was also an independent and significant pre-
dictor for LRTI (OR 3.4; 95% CI: 1.3–9.8; P = 0.018) only in
adults. Increasing age was also a significant predictor for
LRTI (OR 1.1; 95% CI: 1.0–1.3; P = 0.048) and pneumonia
(OR 1.2; 95% CI: 1.1–1.4 P = 0.003) among all patients.
Post-hoc sensitivity analyses did not affect our risk estimates
and the above findings (Table 4, Additional file 1: Tables S3,
S5 and S7).
Discussion
Two important observations made in our study were that
1) RSV-infected immunocompromised adults (mainly eld-
erly) presented with more severe outcomes compared to
children; and that 2) adult patients with solid tumors or
leukaemia and those requiring chronic immunosuppres-
sion for vasculitis were significantly more likely to be
admitted to hospital for RSV disease compared to
HSCT recipients.
Table 3 Predictors for ARTI-attributable hospital admission among all immunocompromised patients and stratified by age-groups
(adults vs children)
N = 215 (152 adults, 63 children)a Univariable analyses Multivariable analyses
OR (95% CI) OR (95% CI) P value
Increasing age (by 10Y range) All 1.0 (0.9;1.1) 1.0 (0.9;1.2) 0.558
Adults 1.6 (1.3;2.1) 1.4 (1.0;1.8) 0.027
Children 0.6 (0.2;1.8) – –
Bacterial co-infection All 1.6 (0.8;3.4) 1.5 (0.7;3.3) 0.340
Adults 2.2 (0.9;5.2) 1.7 (0.6;4.5) 0.286
Children 0.8 (0.2;3.3) 1.0 (0.2;4.6) 0.995
ALC All 1.0 (1.0;1.2) 1.0 (1.0;1.2) 0.420
Adults 1.0 (1.0;1.2) 1.0 (1.0;1.2) 0.436
Children 0.8 (0.5;1.2) 0.8 (0.5;1.2) 0.309
SOT All 2.1 (0.9;5.1) 1.9 (0.8;4.6) 0.166
Adults 2.1 (0.9;5.4) 1.6 (0.6;4.4) 0.312
Children 1.7 (0.1;53.3) – –
Leukemia/lymphoma All 4.0 (1.7;9.5) 3.9 (1.7;9.7) 0.002
Adults 3.0 (1.0;9.3) 1.5 (0.4;5.2) 0.556
Children 7.5(1.1;149.7) – –
Solid tumor All 7.2 (2.6;21.2) 7.4 (2.7;21.9) < 0.001
Adults 7.4 (2.1;28.4) 5.2 (1.4;20.9) 0.015
Children 10.5 (1.2;240.1) – –
Chronic immunosuppressive medication All 10.5 (3.7;32.9) 9.5 (3.3;30.2) < 0.001
Adults 8.2 (2.6;28.4) 4.1 (1.1;16.0) 0.034
Children 35.0 (2.6;1450.5) – –
PID All 4.3 (0.7–26.1) 4.5 (0.7;29.0) 0.097
Children 10.5 (0.8–298.2) – –
Absolute lymphocyte counts (ALC), Hematopoietic stem cell recipients (HSCT), Primary immunodeficiency disease (PID) Solid organ transplant (SOT), Acute-respiratory-tract
infection (ARTI)
aN refers to the total number of patients included in all multivariable analyses for whom information on all predictors and outcomes were available. 24 patients
(23 adults – 1 child) were excluded from univariable and multivariable analyses because of missing values for nALC
Limited sample size in the pediatric subset limited the number of predictors, which could be included in multivariable analyses (−)
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The overall burden of RSV among health-seeking pop-
ulations has mostly been evidenced in young children,
adults above 65 years of age, pregnant women or im-
munocompromised patients in whom equivalent disease
burden to influenza has been reported [19–21]. The esti-
mation of severe RSV infections in Switzerland is limited
by the lack of an active RSV surveillance system. However,
from our findings, we estimated that less than 10% RSV
Table 4 Predictors of progression to LRTI and pneumonia among all immunocompromised patients and stratified by age-groups
(adults vs children)
Univariable analyses Multivariable analyses
OR (95%CI) OR (95% CI) P value
Outcome: LRTI N = 215 (152 adults, 63 children)a
Increasing age (by 10Y range) All 1.2 (1.0;1.3) 1.1 (1.0;1.3) 0.048
Adults 1.3 (1.1;1.7) 1.2 (1.0;1.5) 0.128
Children 0.9 (0.3;2.8) – –
Bacterial co-infection All 3.3 (1.5;7.5) 3.4 (1.5;8.2) 0.005
Adults 3.2 (1.3;8.6) 3.4 (1.3;9.8) 0.018
Children 3.4 (0.8;17.5) 4.1 (0.9;24.6) 0.084
ALC All 1.0 (1.0;1.2) 1.0 (1.0;1.2) 0.501
Adults 1.1 (1.0;1.3) 1.0 (1.0;1.3) 0.580
Children 1.0 (0.6;1.4) 0.9 (0.6;1.3) 0.457
Type immunosuppression (compared to HSCT)
SOT All 0.9 (0.4;1.9) 0.7 (0.3;1.4) 0.294
Adults 1.0 (0.4;2.1) 0.7 (0.3;1.5) 0.344
Children 0.7 (0.1;6.4) – –
Leukemia/lymphoma All 1.0 (0.5;2.0) 1.0 (0.5;2.3) 0.935
Adults 2.0 (0.7;6.0) 1.2 (0.4;3.9) 0.791
Children 0.5 (0.1;2.7) – –
Solid tumor All 1.0 (0.4;2.5) 1.0 (0.4;2.6) 0.985
Adults 1.2 (0.4;3.8) 0.8 (0.2;2.8) 0.718
Children 0.7 (0.1;4.4) – –
Chronic immunosuppressive medication All 3.4 (1.2;10.4) 2.6 (0.9;8.3) 0.077
Adults 4.0 (1.3;15.6) 2.4 (0.7;10.2) 0.204
Children 2.0 (0.2;21.4) – –
PID All 0.6 (0.1;3.1) 0.7 (0.1;4.3) 0.724
Children 0.7 (0.1;6.4) – –
Outcome: LRTI N = 215 (152 adults, 63 children)a
Increasing age (by 10Y range) All 1.2 (1.1;1.4) 1.2 (1.1;1.4) 0.003
Bacterial co-infection All 3.1 (1.5;6.6) 3.6 (1.6;8.4) 0.002
ALC All 1.0 (1.0;1.1) 1.0 (1.0;1.1) 0.439
Type immunosuppression (compared to HSCT)
SOT All 0.7 (0.3;1.7) 0.5 (0.2;1.1) 0.094
Leukemia/lymphoma All 0.9 (0.4;2.1) 1.0 (0.4;2.5) 0.956
Solid tumor All 1.2 (0.5;3.2) 1.3 (0.4;3.6) 0.639
Chronic immunosuppressive medication All 2.0 (0.8;5.4) 1.4 (0.5;3.8) 0.540
PID All 0.4 (0.0;2.8) 0.7 (0.0;5.0) 0.721
Absolute lymphocyte counts (ALC); Hematopoietic stem cell recipients (HSCT), Primary immunodeficiency disease (PID); Solid organ transplant (SOT);
aN refers to the total number of patients included in all multivariable analyses for whom information on all predictors and outcomes was available. 24 patients (23
adults – 1 child) were excluded from univariable and multivariable analyses because of missing values for ALC
Limited sample size in the pediatric subset limited the number of predictors which could be included in multivariable analyses for the outcome LRTI (−)
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positive samples were collected from immunocomprom-
ised subjects, thus suggesting either that RSV only affects
a very small subset of immunococompromised patients or
insufficient diagnostic screening [6, 11, 22, 23].
We have documented important differences in out-
comes of RSV infections among immunocompromised
children compared with immunocompomised adults.
While children were more frequently admitted to hospital
for their RSV infection compared to adults, most inpa-
tients admitted to the ICU, requiring invasive ventilation
or those who died were adults, thus suggesting worse out-
comes among our adult inpatients. In addition, elderly pa-
tients were significantly more likely to present with
pneumonia compared to children. Furthermore, as sup-
ported in another study [6], over one third of our RSV-
infected immunocompromised adult cohort presented
with pneumonia for whom a transfer to the ICU was re-
quired resulting in mortality rates of almost 20%. These
important findings highlight the potential consequences of
RSV infection among adults with underlying immunodefi-
ciencies and may suggest that these patients would specif-
ically benefit from preventive strategies.
As suggested in another study [6], bacterial co-infection
also contributed undoubtedly to progression towards
LRTI and pneumonia, likely as a result of RSV-induced in-
juries to respiratory epithelium thereby increasing bacter-
ial adherence [11, 24, 25].
Studies focusing on the severity of viral co-infections
have resulted in different findings likely as a result of in-
cluding various age groups and breadth of illness severity
and limited sample sizes [22, 26, 27]. While viral co-
infections were documented among one-third of our
pediatric patient-population and 20% of the adult one, no
significant association between viral co-infections and our
outcomes of interest were documented, in line with find-
ings from a recent systematic review [28]. Furthermore,
post-hoc sensitivity analyses excluding patients with viral
co-infections did not affect our risk estimates.
The burden of RSV infections has been widely and
consistently evidenced among HSCT recipients, with
much less known in other immunocompromised patient
populations [6, 9, 11]. Some studies [29, 30] reported se-
vere RSV outcomes among SOT recipients and children
with congenital immunodeficiencies, without being con-
sistent throughout the literature [31]. To our knowledge,
this is the first report showing that adult patients requir-
ing chronic immunosuppression mainly for Connective
Tissue Disease (CTD) or vasculitis and those with solid
tumors were at highest risk for hospital admission when
compared to HSCT recipients. Furthermore, discrepan-
cies between our findings and those in published litera-
ture were not influenced by timing after transplantation
as post-hoc sensitivity analyses excluding HSCT recipi-
ents infected 2 years after their transplantation, did not
affect our risk estimates. We also reported increased se-
verity of RSV infections among patients with leukaemia
in line with published literature [32, 33]. These import-
ant findings highlight the burden of RSV disease among
various categories of immunocompromised patients
other than HSCT recipients.
Important strengths of our study include a large variety
of immunocompromised adults and children categorized in
6 mutually exclusive categories. All subgroup analyses were
defined a priori and post hoc sensitivity analyses confirmed
robustness of the results. The inclusion of outpatients en-
abled the use of hospital admission as a measure of clinical
severity in addition to LRTI and pneumonia thus support-
ing consistency of our findings. Potential limitations of our
study relate to its retrospective design and laboratory-based
collected data, which may have led to selection bias. How-
ever all consecutive immunocompromised patients with
URT or LRT symptoms were systematically tested for re-
spiratory viruses according to local guidelines, which may
have reduced the risk of selection bias. Second, the inclu-
sion of adults and children and the lack of adjustment for
other comorbidities, may have biased our findings towards
more severe outcomes among adults, as children are rou-
tinely screened for RSV infections whereas adults are
swabbed for RSV while experiencing more severe symp-
toms. However, half of our adult RSV-positive cohort was
screened in an ambulatory setting while consulting with
mild symptoms and sensitivity analyses excluding children
detected by rapid antigen assays did not affect our risk es-
timates. As such, we believe, that our findings were still
suggestive of worse clinical outcomes in RSV-infected im-
munocompromised adults. Third, our estimation of bac-
terial co-infections may have been underestimated as BAL
are rarely performed in children and pneumonia rarely re-
sults in positive blood cultures. Finally, the lack of a com-
parator group of patients without any other identified
pathogen would have better delineated the attribution of
disease burden solely to RSV.
Conclusions
In conclusion, our study conducted on a small sub-set of
patients, suggests a higher burden of RSV disease in im-
munocompromised adults compared to children, more
specifically among patients with solid tumors, leukae-
mia/lymphoma or those requiring chronic immunosup-
pression for CTD or vasculitis.
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